Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)

Not Applicable

Completed

• Conditions: Acute Mountain Sickness
• Interventions: Device: Control; Device: Theravent

• Registration Number: NCT01842906
• Lead Sponsor: Stanford University

Brief Summary

The study is examining if an over-the-counter device (Theravent) worn while sleeping can reduce acute mountain sickness upon awakening in a high altitude trekking population.

Detailed Description

The specific aim of this study is to evaluate if an inexpensive and disposable end-expiratory pressure device can prevent acute mountain sickness (AMS). AMS is a common disorder found in 25-75% of hikers and trekkers in N. America and Europe who expediently ascend high altitude (\>8,000 ft). This environmental malady is insidious in onset and prevention is necessary not just to limit progression to severe or fatal disease, but also to limit physiologic deterioration in those who seek enjoyment or employment at high altitudes. One of the hallmarks of both healthy and sick individuals sleeping at high altitude is an oscillating pattern of respiration marked by periods of hyperventilation alternating with apnea or hypopnea. This distressing "periodic breathing" pattern leads to a feeling of suffocation, prevents restful sleep, and the hypoxic events may well worsen ensuing AMS. Prior studies have found positive end-expiratory pressure (PEEP) an effective non-pharmacologic method to prevent nocturnal desaturations and decreasing both AMS incidence and severity.

Traditionally, PEEP devices are cumbersome and expensive, and while showing promising efficacy, are limited by both cost and portability as a useful non-pharmacologic option for AMS prophylaxis. The SLEEP-AID methodology is designed to prospectively enroll participants, randomized in a double blind placebo-controlled fashion to either the intervention \[Theravent (Ventus Medical) which is single use, inexpensive, and very small\] or a visually identical "sham" placebo group, and gather physiologic data to accurately reflect sleep patterns of high altitude travelers and objective as well as subjective outcomes of the intervention. The benefit of this approach will be to provide definitive data in a large and diverse cross section of a real hiking population that is generalizable to the majority of tens of millions of hikers, climbers, and high altitude tourists in the United States, Europe, Asia, and South America.

Study Timeline

• Study First Submitted: 2013-04-22
• Study First Submitted QC: 2013-04-29
• Study First Posted: 2013-04-30
• Study Start: 2013-10
• Primary Completion: 2013-12
• Study Completion: 2014-10
• Results First Submitted: 2016-08-09
• Results First Submitted QC: 2017-03-09
• Results First Posted: 2017-04-20
• Status Verified: 2018-11
• Last Update Submitted: 2018-11-21
• Last Update Posted: 2018-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 219

Inclusion Criteria

• ages 18-65
• Lake Louise Score (LLS) of < 3
• Have not taken NSAIDs, acetazolamide, or corticosteroids in the prior week
• Have not traveled above 4200 m in the prior week.
• First night in Pheriche or Dingboche

Read More

Exclusion Criteria

• Unable to read the consent form
• Taken NSAIDs, acetazolamide, or corticosteroids in the week prior to study enrollment.
• Hazardous medical conditions which precludes the ability to tolerate the experimental device.
• Pregnancy or suspected pregnancy.
• Participants who are younger than 18 years of age and more than 65.
• Travel to or above 4200m in the preceding week.
• Diagnosis of AMS upon enrollment (LLS ≥3 with symptoms of headache)
• Previously diagnosed obstructive sleep apnea
• Current symptoms of nasal congestion, rhinorrhea, sinusitis, upper respiratory infection, asthma, COPD exacerbation, pneumonia, bronchitis, or other disease of the respiratory tract.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Control	A visibly identical sham device that does not provide positive end expiratory pressure.
Theravent	Theravent	A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.

Primary Outcome Measures

Name	Time	Method
Incidence of Acute Mountain Sickness	Approximately 10 hours	Acute mountain sickness will be measured by Lake Louise Criteria and diagnosed as LLC \> or = to 3 with presence of a headache. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.

Secondary Outcome Measures

Name	Time	Method
Number of Nocturnal Desaturations	Approximately 10 hours	Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.
Nocturnal Awakenings	approximately 10 hours	Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.
Acute Mountain Sickness Severity	approximately 10 hours	Severity of acute mountain sickness will be evaluated by the Lake Louise Criteria (0-15 point scale) with higher scores representing more severe symptoms. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.

Trial Locations

Locations (1)

Nepal; 🇳🇵 Pheriche & Dingboche, Khumbu, Nepal